Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.5K

Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients

Pabitra Basnyat1, Sanna Hagman1, Marcin Kolasa1

  • 1Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland.

Multiple Sclerosis and Related Disorders
|July 22, 2015
PubMed
Abstract

Insights

Soluble L-selectin (sL-selectin) levels correlate with the anti-JC Virus (JCV) antibody index in relapsing-remitting MS patients treated with natalizumab. This finding suggests sL-selectin may serve as a biomarker for predicting progressive multifocal leukoencephalopathy (PML) risk.

Area of Science:

  • Neuroimmunology
  • Virology
  • Biomarker Discovery

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a risk in relapsing-remitting MS (RRMS) patients on natalizumab.
  • Low levels of L-selectin-expressing CD4+ T cells are associated with PML risk.

Purpose of the Study:

  • To investigate the correlation between serum soluble L-selectin (sL-selectin) levels and the anti-JC Virus (JCV) antibody index in RRMS patients undergoing natalizumab treatment.

Main Methods:

  • Serum sL-selectin levels were measured using ELISA.
  • The anti-JCV antibody index was determined via a second-generation ELISA assay.
  • Study included 44 RRMS patients on natalizumab, 30 on interferon beta, and 25 healthy controls.

Main Results:

  • A significant positive correlation (r=0.402, p=0.007) was observed between sL-selectin levels and anti-JCV antibody indices in natalizumab-treated RRMS patients.
  • No significant correlation was found in patients treated with interferon beta.
  • The correlation strengthened in JCV seropositive patients on natalizumab for over 18 months (r=0.529, p=0.043).

Conclusions:

  • Serum sL-selectin levels are linked to anti-JCV antibody index values in natalizumab-treated RRMS patients.
  • sL-selectin may be associated with cellular L-selectin expression.
  • Further research is warranted to evaluate serum sL-selectin as a potential biomarker for predicting PML risk.
Keywords:
Anti-JCV antibody indexBiomarkersMultiple sclerosisNatalizumabProgressive multifocal leukoencephalopathysL-selectin

More Related Videos

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

21.0K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Related Concept Videos

Selectins01:25

Selectins

Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
4.8K
Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or...
18.7K
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
30
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
4.6K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.9K